Interpace Diagnostics Group, Inc.
(NASDAQ : IDXG)

( )
IDXG PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Services » Servicestothe Health Industry
symbolcompany%chnglast%shortavg$volume
CERNCerner Corporation
1.85%63.837.6%$174.87m
LHLaboratory Corporation of America Holdings
4.85%151.252.3%$120.53m
DGXQuest Diagnostics Incorporated
9.27%93.084.2%$110.37m
SRCLStericycle, Inc.
1.71%57.166.3%$67.80m
HCSGHealthcare Services Group, Inc.
1.28%33.996.7%$35.35m
OMCLOmnicell, Inc.
4.42%75.2910.5%$21.85m
HMSYHMS Holdings Corp.
1.80%28.901.9%$15.02m
MDRXAllscripts Healthcare Solutions, Inc.
3.10%9.659.9%$14.91m
CPSIComputer Programs and Systems, Inc.
1.15%29.8632.6%$3.58m
HSTMHealthStream, Inc.
-5.15%25.806.7%$2.70m
IDXGInterpace Diagnostics Group, Inc.
8.70%0.753.3%$0.25m
PMDPsychemedics Corporation
-1.36%13.750.7%$0.21m
PLXProtalix Biotherapeutics, Inc.
1.03%0.425.8%$0.12m
BASIBioanalytical Systems, Inc.
2.08%1.960.3%$0.04m
STRMStreamline Health Solutions, Inc.
-2.32%0.970.3%$0.01m

Company Profile

Interpace Diagnostics Group, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.